Table 1. DESIGN/ BD2DECIDE patient characteristics.
| DESIGN training cohort (n = 301) | BD2DECIDE validation cohort (n = 143) | P-value | |
|---|---|---|---|
| Median (range) | Median (range) | ||
| GTVprim Volume (cm3) | 21.28 (0.65–176.10) | 19.82 (0.54–157,28) | 0.82 |
| Age (years) | 61 (36–80) | 60 (41–78) | 0.52 |
| Number of pts (%) | Number of pts (%) | ||
| WHO PS | <0.001 | ||
| 0 | 0 (0) | 120 (83.9) | |
| 1 | 79 (26.2) | 20 (14.0) | |
| 2 | 139 (46.2) | 3 (2.1) | |
| 3 | 10 (3.3) | 0 (0) | |
| Missing | 73 (24.3) | 0 (0) | |
| Clinical TNM (T), 7th Edition | 0.08 | ||
| cTX | 0 (0) | 0 (0) | |
| cT1 | 14 (4.7) | 3 (2.1) | |
| cT2 | 63 (20.9) | 25 (17.5) | |
| cT3 | 106 (35.2) | 68 (47.6) | |
| cT4 | 118 (39.2) | 47 (32.9) | |
| Clinical Nodal stage (N), 7th Edition | 0.01 | ||
| cNX | 1 (0.3) | 0 (0) | |
| cN0 | 41 (13.6) | 37 (25.9) | |
| cN1 | 41 (13.6) | 19 (13.3) | |
| cN2 a-b-c | 209 (69.5) | 79 (55.2) | |
| cN3 | 9 (3.0) | 8 (5.6) | |
| HPV status (P16 stain) | <0.001 | ||
| Negative | 207 (68.8) | 64 (44.8) | |
| Positive/ Unknown | 94 (31.2) | 79 (55.2) | |
| Treatment | |||
| Chemotherapy regimen | <0.001 | ||
| • Platin | 292 (97.0) | 81 (56.6) | |
| • Platin + others | 9 (3.0) | 23 (16.1) | |
| • Cetuximab | 0 (0) | 39 (27.3) | |
| Cumulative radiotherapy dose high-risk CTV | 70 (60–84) Gy | 70 (20–76) Gy | |
| Tumor site | |||
| Oropharynx | 145 (48.2) | 49 (34.3) | 0.02 |
| Larynx | 57 (18.9) | 39 (27.3) | |
| Hypopharynx | 99 (32.9) | 55 (38.5) |